This bill amends the definition of medical cannabidiol in Iowa law by replacing the existing language in Section 124E.2, subsection 10. The new definition specifies that medical cannabidiol encompasses any species of the cannabis plant or any mixture or preparation thereof, including whole plant extracts and resins. It outlines the acceptable forms of delivery for medical cannabidiol, which include oral forms (such as tablets, capsules, liquids, tinctures, and sublingual forms), topical forms (including gels, ointments, creams, lotions, and transdermal patches), and inhaled forms (limited to nebulizable inhaled forms, vaporizable dried raw cannabis, and other vaporizable forms).

The bill aims to clarify and expand the types of cannabis products that can be classified as medical cannabidiol, thereby potentially enhancing access for patients who may benefit from these various forms of delivery. The inclusion of specific product types reflects a more comprehensive approach to the medical use of cannabis in Iowa.

Statutes affected:
Introduced: 124E.2